Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Role of Exercise and Energy Conservation in the Management of Fatigue in Patients with NSCLC Receiving Immune-Oncology Therapy

2021 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Cancer-related fatigue occurs on most days over the course of the disease, lasts at least 2 weeks, and interferes with daily activities.1 Throughout the course of the disease, fatigue is the most frequently reported symptom in patients with lung cancer.1

Antineoplastic therapies are known to cause treatment-related tiredness, complicating an already difficult situation. Fatigue is the most common adverse event in patients on immune checkpoint inhibitors, which are the new standard of care in non–small-cell lung cancer (NSCLC) treatment.1

Exercise and physical activity, according to a significant body of data, improves the general health of patients with cancer and may help them live longer.2 Physical activity has been linked to a lower incidence of a variety of cancers in humans, and some evidence suggests that it may have a clinical benefit for patients with cancer.3 Exercise causes immune system cells to mobilize and redistribute to different bodily compartments, and exercise has been demonstrated to cause immunologic alterations in the tumor microenvironment in preclinical models. This suggests that combining exercise and immunotherapy may have a synergistic impact.3 The advantages of exercise include physical well-being, calm, freedom, relaxation, and improved sleep quality.

Given the substantial link between exercise and better outcomes in patients with cancer, strengthening systemic immunity and patient immunologic responses through exercise could be a complementary method to boosting immunotherapy responses, allowing for a more effective therapeutic response.2 Numerous studies have recently been published that provide some intriguing information about how exercise affects immune cell populations and function. The scientific premise that physical activity and exercise can help the immune system recover and optimize its responses to cancer is well-documented.2

The fatigue caused by cancer and further fatigue caused by immune checkpoint inhibitor treatment is an unfortunate aspect of cancer, including NSCLC. To maintain a patient’s functionality, nurses should become proactive advocates for physical activity throughout and after therapy. A well-thought-out progressive program of restorative exercise and energy-saving skills can help manage fatigue as a therapeutic complement to antineoplastic treatment. Aerobic exercise for at least 30 minutes a day for 5 days per week is an ideal exercise routine for patients with cancer to strive toward, if they can manage.3

References

  1. Almeida C, Chemela R. The role of physical exercise and energy conservation in the management of fatigue in NSCLC patients under IO. Ann Oncol. 2021;32(suppl 5):S1278.
  2. Gustafson MP, Wheatley-Guy CM, Rosenthal AC, et al. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J ImmunoTherapy Cancer. 2021;9:e001872.
  3. Olofsson GH, Jensen AWP, Idorn M, Straten PT. Exercise oncology and immune-oncology; a (future) dynamic duo. Int J Mol Sci. 2020;21:3816.
Related Items
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
NSCLC Year in Review Introduction
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Impact of Symptom Severity on Multidisciplinary Tumor Board Treatment Decisions
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Phase 2 Study Results Demonstrate Sotorasib Efficacy
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
FDA Grants Accelerated Approval of Sotorasib for Patients with NSCLC Harboring KRAS Mutations
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Impact of Hyperglycemia in Patients with Advanced NSCLC with PD-L1 ≥50% Treated with Frontline Pembrolizumab
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.